CAPAIR Study

Cicatricial Alopecia Patient Assessment & Impact Report Study

There are countless numbers of underserved patients suffering from permanent, inflammatory hair loss with limited clinical options for treatment. There is not a single approved treatment for scarring alopecia.

There are no known, approved, or targeted therapies to treat the disease since the cause of scarring alopecia is not known. There is little to no interest and/or research investigating the cause because there is lack of comprehensive patient data and weak evidence to support current therapies.

In 2022, SAF conducted the first-of-its-kind patient survey as a first step in gathering patient data called the Cicatricial Alopecia Patient Assessment and Impact Report (CAPAIR) survey. Data was collected from 1048 patients in five categories: medical history, understanding your diagnosis, physician access and knowledge, treatments, time & financial impact and quality of life. The anonymous survey with over 80 questions and multiple data points, is rich with data and being used in multiple ways to bring attention to the disease.

CAPAIR data was presented at the 2024 American Hair Research Society’s World Congress and sections of data are being analyzed by industry, physicians, and researchers.